Unlike hydrophilic statins such as pravastatin and rosuvastatin, which mainly suppress CHO biosynthesis by the liver, lovastatin is more bioavailable in the periphery and thus seems to be suitable for targeting MVP in tumor cells [67,68]. The gene discussed is MVP; the disease is neoplasm.